Key Advisors

Mervyn Turner, Ph.D.

Mervyn Turner, Ph.D.

Mervyn Turner, Ph.D., accumulated over 25 years of experience at Merck Research Laboratories in pharmaceuticals drug discovery, research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For 7 years, he was head of world-wide licensing and external research at Merck, during a period of rapid expansion in Merck’s partnering activities. He became Merck’s first Chief Strategy Officer and a member of the senior executive team in 2008, before retiring from the company in 2011.

Dr. Turner currently operates his own consulting business. He is the Chairman of the Board of LUNAC, UK. He served on the Board of Preventice, LLC, Rochester, Minnesota until the merger with eCardio. He also serves on the Board of EnGeneIC, Sydney, Australia.

He was a member of the Steering Committee of the Seeding Drug Discovery Initiative of the Wellcome Trust, UK. He currently serves as an Advisor to Bay City Capital, San Francisco; to Adagene, Suzhou, China; and to Bridge Medicines, NYC. He is a member of the SAB for Spinogenix, San Diego, and Blade Therapeutics, San Francisco. He is also a Senior Advisor to the Lazard Health Care group, New York.

Back to Key Advisors